Roth Capital initiated coverage of vTv Therapeutics (VTVT) with a Buy rating and $58 price target The firm believes cadisegliatin is positioned to become the first approved oral adjunct for type 1 diabetes and reports that its key opinion leader consultant is “bullish” and expects approval with broad adoption if the Phase 3 program replicates the “compelling” Phase 2 profile.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTVT:
- vTv Therapeutics: Late-Stage Cadisegliatin Data, Differentiated Mechanism, and Partnered T2D Expansion Underpin Buy Rating and $40 Target
- vTv Therapeutics initiated with a Buy at TD Cowen
- Paradigm-Shifting Potential in Type 1 Diabetes: vTv Therapeutics’ Cadisegliatin Supports Buy Rating and Significant Upside
- vTv Therapeutics price target raised to $47 from $36 at H.C. Wainwright
- vTv submits cadisegliatin study protocol to Department of Health Abu Dhabi